Abstract
The Distribution Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter distribution deals.
The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner' s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains over 500 links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner' s flexibility on a wide range of important issues, many of which will have a significant impact on each party' s ability to derive value from the deal.
The initial chapters of this report provide an orientation of distribution dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in distribution as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous case studies to enable understanding of both pure distribution deals and multicomponent deals where distribution forms a part.
Chapter 4 provides a review of the leading distribution deals since 2000. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of distribution contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of all distribution agreement contracts available in the public domain. Each chapter is organized by A-Z, stage of development at signing, and therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2000. In conclusion, this report provides everything a prospective dealmaker needs to know about distribution as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in distribution dealmaking
- 2.1. Introduction
- 2.2. Definiton of distribution dealmaking
- 2.3. Trends in distribution deals since 2000
- 2.4. Pure deals and multi-component deals
- 2.5.1. Attributes of pure distribution deals
- 2.5.2. Attributes of distribution in multi-component deals
- 2.6. Aligning partners to make the distribution agreement work
- 2.7. The emergence of direct to pharmacy distribution in Europe
- 2.7.1. The role of consolidated distribution
Chapter 3 - Overview of distribution deal structure
- 3.1. Introduction
- 3.2. Pure versus multi-component distribution deals
- 3.3. Pure distribution agreement structure
- 3.3.1. Example distribution agreements
- 3.3.1.a. Case study 1: BioSite - Fisher Scientific - January 2006
- 3.3.1.b. Case study 2: Inverness Medical Innovations - Matritech - November 2006
- 3.3.1. Example distribution agreements
- 3.4. Distribution rights as part of a wider alliance agreement
- 3.4.1. Example distribution clauses
- 3.4.1.a. Case study 3: Ipsen - Aesthetica - March 2006
- 3.4.1.b. Case study 4: Gilead - Bristol-Myers Squibb - September 2006
- 3.4.1. Example distribution clauses
Chapter 4 - Leading distribution deals
- 4.1. Introduction
- 4.2. Top distribution deals by value
- 4.3. Top pure distribution deals
- 4.4. Top distribution deals signed by bigpharma
- 4.5. Most active distribution dealmakers
- 4.6. Bigpharma distribution deal activity
Chapter 5 - Bigpharma distribution agreements
- 5.1. Introduction
- 5.2. How to use distribution agreements
- 5.3. Company distribution agreement listings
- Abbott
- Actavis
- Akzo Nobel (Organon)
- Allergan
- Altana
- Amgen
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Bayer Schering Pharma AG
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- King
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono KGaA
- Mitsubishi
- Novartis AG
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Roche
- Sanofi-Aventis
- Schering Plough
- Serono
- Shionogi Seiyaku
- Shire
- Solvay
- Takeda
- Tanabe Seiyaku
- TAP Pharmaceuticals
- Teva
- UCB
- Watson
- Wyeth
Chapter 6 - Distribution agreement directory 2003-7
- 6.1. Introduction
- 6.2. Company A-Z
- 6.3. By therapy area
- Accident/Hospital/Trauma
- Blood/Lymphatic System
- Cardiovascular
- Central nervous System
- Dermatology
- Gastrointestinal
- Genitourinary
- Genetic
- Autoimmune/Inflammatory
- Infection
- Metabolism
- Musculoskeletal
- Oncology
- Respiratory
- Sensory Organ / Oral Health
- 6.4. By stage of development at signing
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Registration
- Market
- Appendices
- Appendix 1 - Distribution references
- Appendix 2 - Resources
- Appendix 3 - Deal type definitions
- Appendix 4 - Example distribution contract document
- About CurrentPartnering
- Recent report titles from CurrentPartnering
- Order Form - Reports
- Order form - Company Dealmaking Profiles
- Order Form - Report Update Subscription
- Order Form - CD-Rom
Figures in report
- Figure 1: Definition of distribution dealmaking
- Figure 2: Trends in distribution deal announcements, 2000-2007
- Figure 3: Distribution deals signed at what phase of development, 2000-2007
- Figure 4: Pure versus multi-component distribution deal announcements, 2000-2007
- Figure 5: Stage of development at which pure and multi-component distribution deals are announced 2000-2007
- Figure 6: Issues in implementing distribution agreements
- Figure 7: Recent consolidated distribution deals
- Figure 8: Components of the distribution deal structure
- Figure 9: Top 50 distribution deals by value since 2003
- Figure 10: Top pure distribution deals by value since 2003
- Figure 11: Top distribution deals signed by bigpharma value since 2003
- Figure 12: Most active distribution dealmakers 2003-7
- Figure 13: Characteristics of active distribution dealmakers
- Figure 14: Bigpharma - top 50 - distribution deals since 2003
- Figure 15: Online partnering resources
- Figure 16: Deal type definitions
- Figure 17: Distribution agreement between Amphastar and Andrx, May 2005
